Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas:
Summarizing Current Efficacy and Safety Data
Bi-specific antibodies for Non-hodgkin’s lymphoma treatment in Veterans Affairs patients: Current treatments, limitations and new promises
Post-Test/Evaluation

Exit Survey
Questions marked with a * are required
21%
Contact Information
Credentials/Degree (MD, DO, etc.)
Date of  Participation
A 65-year-old male veteran presents with diffuse large B-cell lymphoma (DLBCL). Which of the following would be an indicator for prescribing a bispecific antibody?
A 65-year-old male veteran presents with diffuse large B-cell lymphoma (DLBCL). Which of the following would be an indicator for prescribing a bispecific antibody?
Which of the following receptors do the FDA-approved or trial bi-specific antibodies for treating NHL recognize?
Which of the following receptors do the FDA-approved or trial bi-specific antibodies for treating NHL recognize?
Obinutuzumab pretreatment for cytokine release syndrome (CRS) mitigation is administered for which of the following bispecific antibodies?
Obinutuzumab pretreatment for cytokine release syndrome (CRS) mitigation is administered for which of the following bispecific antibodies?
Powered by QuestionPro